Page 61 - CIBEREHD2016-ENG

• Development of new human hepatic cell models with differentiated hepatic phenotype and able to mimic idiosyncratic responses.
• Hepatotoxicity by drugs: Molecular mechanisms and new biomarkers for their translation into the clinic in iatrogenic steatosis and cholestasis.
• Etiology of nonalcoholic fatty liver: transcriptional mechanisms involved.
• Advanced diagnosis, monitoring, prognosis and clinical trials in drug hepatotoxicity.
• Cell transplantation and other personalized hepatic cell therapies.
Most relevant scientific articles
• Prieto J., Leon M., Ponsoda X., Sendra R., Bort R., Ferrer-Lorente R. et al. Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming. Nature Communications. 2016;7.
• Garcia-Canaveras J.C., Castell J.V., Donato M.T., Lahoz A.. A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. Scientific Reports. 2016;6.
• Gomez-Lechon M.J., Tolosa L.. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. Archives of Toxicology. 2016;:1-13.
• Bozic M., Guzman C., Benet M., Sanchez-Campos S., Garcia-Monzon C., Gari E. et al. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. Journal of Hepatology. 2016.
• Tolosa L., Gomez-Lechon M.J., Lopez S., Guzman C., Castell J.V., Donato M.T. et al. Human upcyte hepatocytes: Characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing. Toxicological Sciences. 2016;152(1):214-229.
Hightlights
PROJECTS
• Fast metabolomic assessment of donor liver quality prior to transplant. Roche Organ Transplant Research Foundation (2014-2016)
• Aproximaciones metabonómicas para el estudio de la hepatotoxicidad idiosincrásica con base metabólica y la identificación del agente causal. Instituto de Salud Carlos III-FIS. Proyecto PI 13/00986 (2014-2016).
• Esteatosis hepática por medicamentos: nuevos mecanismos y biomarcadores aplicables al desarrollo farmacéutico y a una terapia más racional en pacientes con síndrome metabólico. Instituto de Salud Carlos III-FIS. Proyecto PI13/01470 (2014-2016)
• An integrated european ‘flagship’ program driving mechanism-based toxicity testing and risk assessment for the 21st century (EU-ToxRisk) H2020 EU Research Project 681002 (2016-2020)
• Hepatotoxicidad idiosincrásica por fármacos: estrategias in vitro para un diagnóstico retrospectivo, atribución de la causalidad y evaluación del potencial riesgo clínico en pacientes susceptibles. Instituto de Salud Carlos III-FIS. Proyecto PI 16/00333 (2017-2019).
• Improving feasibility of liver cell therapy: new cell sources and strategies to improve the clinical outcome. Instituto de Salud Carlos III-FIS. Proyecto CP16/0097 (2017-2019).
EHD
research Groups 61